二甲双胍抗肿瘤机制及其对靶向药物疗效的影响

摘要/Abstract

摘要：肿瘤已进入精准治疗时代，分子靶向是肿瘤治疗的一种新趋势，肿瘤的异常代谢状态及靶向代谢药物与肿瘤靶向药物联合应用已经成为肿瘤研究的新的热点之一。大量研究表明靶向代谢药物二甲双胍与多种靶向药物联合应用，具有协同抗肿瘤等作用。未来靶向代谢药物与抗肿瘤靶向药物联合应用能为抗肿瘤治疗提供新的策略。

郜辉，易善永，杨斌，马西文，赵玲. 二甲双胍抗肿瘤机制及其对靶向药物疗效的影响[J]. 国际肿瘤学杂志, 2018, 45(12): 747-750.

Gao Hui, Yi Shanyong, Yang Bin, Ma Xiwen, Zhao Ling. Antitumor mechanism of metformin and its effect on targeted drugs[J]. Journal of International Oncology, 2018, 45(12): 747-750.

［1］ Warburg O. On the origin of cancer cells［J］. Science, 1956, 123(3191): 309314. DOI: 10.1126/science.123.3191.309. ［2］ Chae YK, Arya A, Malecek MK, et al. Repurposing metformin for cancer treatment: current clinical studies［J］. Oncotarget, 2016, 7(26): 4076740780. DOI: 10.18632/oncotarget.8194. ［3］ Buckanovich RJ, Brown J, Shank J, et al. A phase Ⅱ clinical trial of metformin as a cancer stem cell targeting agent in stage Ⅱc/Ⅲ/Ⅳ ovarian, fallopian tube, and primary peritoneal cancer［J］. Clin Oncol, 2017, 35(Suppl): 5556．［4］ Howell JJ, Ricoult SJ, BenSahra I, et al. A growing role for mTOR in promoting anabolic metabolism［J］. Biochem Soc Trans, 2013, 41(4): 906912. DOI: 10.1042/BST20130041. ［5］ Hawley SA, Gadalla AE, Olsen GS, et al. The antidiabetic drug metformin activates the ampactivated protein kinase cascade via an adenine nucleotideindependent mechanism［J］. Diabetes, 2002, 51(8): 24202425. DOI: 10.2337/diabetes.51.8.2420. ［6］ Brower V. Illuminating the diabetescancer link［J］. Natl Cancer Inst, 2012, 104(14): 10481050. DOI: 10.1093/jnci/djs322. ［7］ Buzzai M, Jones R, Amaravadi R, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53deficient tumor cell growth［J］. Cancer Res, 2007, 67(14): 67456752. DOI: 10.1158/00085472.CAN064447. ［8］ Wang Y, Lin D, Wang X, et al. Data on water consumption in streptozotocininduced diabetic mice by a novel peach gumderived polysaccharide［J］. Data Brief, 2017, 12: 358360. DOI: 10.1016/j.dib.2017.04.022. ［9］ Iliopoulos D, Hirsch HA, Struhl K. Metfomin decreases the dose of chemotherapy for pmlonging tumor remission in mouse xenograftsinvolving multiple cancer ceu types［J］. Cancer Res, 2011, 7l(9): 31963201. DOI: 10.1158/00085472.CAN103471. ［10］ Arrieta O, Barron FB, Padilla MS, et al. Combination of metformin plus TKI vs. TKI alone in EGFR(+) lung adenocarcinoma: a randomized phase Ⅱ study［J］. J Clin Oncol, 2018, 36(suppl): abstr 9013. ［11］ Chen H, Yao W, Chu Q, et al. Synergistic effects of metformin in combination with EGFRTKI in the treatment of patients with advanced nonsmall cell lung cancer and type 2 diabetes［J］. Cancer Lett, 2015, 369(1): 97102. DOI: 10.1016/j.canlet.2015.08.024. ［12］ Pan YH, Jiao L, Lin CY, et al. Combined treatment with metformin and gefitinib overcomes primary resistance to EGFRTKIs with EGFR mutation via targeting IGF1R signaling pathway［J］. Biologics, 2018, 12: 7586. DOI: 10.2147/BTT.S166867. ［13］ Li L, Han R, Xiao H, et al. Metformin sensitizes EGFRTKIresistant human lung cancer cells in vitro and in vivo through inhibition of IL6 signaling and EMT reversal［J］. Clin Cancer Res, 2014, 20(10): 27142726. DOI: 10.1158/10780432.CCR132613. ［14］ Li C, Xue Y, Xi YR, et al. Progress in the application and mechanism of metformin in treating nonsmall cell lung cancer［J］. Oncol Lett, 2017, 13(5): 28732880. DOI: 10.3892/ol.2017.5862. ［15］ Groenendijk FH, Mellema WW, van der Burg E, et al. Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation［J］. Int J Cancer, 2015, 136(6): 14341444. DOI: 10.1002/ijc.29113. ［16］ Casadei Gardini A, Faloppi L, De Matteis S, et al. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: validation study and biological rationale［J］. Eur J Cancer, 2017, 86: 106114. DOI: 10.1016/j.ejca.2017.09.003. ［17］ Hsieh SC, Tsai JP, Yang SF, et al. Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK/JNKmediated NFκBdependent pathway that reduces uPA and MMP9 expression［J］. Amino Acids, 2014, 46(12): 28092822. DOI: 10.1007s0072601418384. ［18］ VazquezMartin A, OliverasFerraros C, DelBarco S, et al. The antidiabetic drug metformin suppresses selfrenewal and proliferation of trastuzumabresistant tumorinitiating breast cancer stem cells［J］. Breast Cancer Res Treat, 2011, 126(2): 355364. DOI: 10.1007/s105490100924x. ［19］ Cufi S, CorominasFaja B, VazquezMartin A, et al. Metformininduced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts［J］. Oncotarge, 2012, 3(4): 395398. DOI: 10.18632/oncotarget.488. ［20］ Sonnenblick A, AgborTarh D, Bradbury I, et al. Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2positive primary breast cancer: analysis from the ALTTO phase Ⅲ randomized trial［J］. Clin Oncol, 2017, 35(13): 14211429. DOI: 10.1200/JCO.2016.69.7722. ［21］ Hirsch HA, Iliopoulos D, Tsichlis PN, et al. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission［J］. Cancer Res, 2009, 69(19): 75077511. DOI: 10.1158/00085472.CAN092994. ［22］ Scharping NE, Menk AV, Whetstone RD, et al. Efficacy of PD1 blockade is potentiated by metformininduced reduction of tumor hypoxia［J］. Cancer Immunol Res, 2017, 5(1): 916. DOI: 10.1158/23266066.CIR160103. ［23］ Eikawa S, Nishida M, Mizukami S, et al. Immunemediated antitumor effect by type 2 diabetes drug, metformin［J］. Proc Natl Acad Sci U S A, 2015, 112(6): 18091814. DOI: 10.1073/pnas.1417636112. ［24］ Watanabe M, Yamamoto H, Eikawa S, et al. Study about the efficacy of metformin to immune function in cancer patients［J］. Acta Med Okayama, 2016, 70(4): 327330. DOI: 10.18926AMO/54514. ［25］ Afzal MZ, Mercado RR, Shirai K, et al. Efficacy of metformin in combination with immune checkpoint inhibitors (antiPD1/antiCTLA4) in metastatic malignant melanoma［J］. J Immunother Cancer, 2018, 6(1): 64. DOI: 10.1186/s4042501803751. ［26］ Kubo T, Ninomiya T, Hotta K, et al. Study protocol: phaseⅠb trial of nivolumab combined with metformin for refractory/recurrent solid tumors［J］. Clin Lung Cancer, 2018, 19(6): e861e864. DOI: 10.1016/j.cllc.2018.07.010. ［27］ Hirsch HA, Iliopoulo D, Struhl K. Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth［J］. Proc Natl Acad Sci U S A, 2013, 110(3): 972977. DOI: 10.1073/pnas.1221055110.

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲.血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊.局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	袁健, 黄燕华.Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[4]	陈红健, 张素青.血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[5]	郭泽浩, 张俊旺.PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[6]	张百红, 岳红云.新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[7]	许凤琳, 吴刚.EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[8]	王盈, 刘楠, 郭兵.抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[9]	张蕊, 褚衍六.基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[10]	高凡, 王萍, 杜超, 褚衍六.肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[11]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东.ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[12]	刘静, 刘芹, 黄梅.基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[13]	杨琳, 路宁, 温华, 张明鑫, 朱琳.炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[14]	王俊毅, 洪楷彬, 纪荣佳, 陈大朝.癌结节对结直肠癌根治性切除术后肝转移的影响[J]. 国际肿瘤学杂志, 2024, 51(5): 280-285.
[15]	张宁宁, 杨哲, 檀丽梅, 李振宁, 王迪, 魏永志.宫颈细胞DNA倍体分析联合B7-H4和PKCδ对宫颈癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(5): 286-291.

二甲双胍抗肿瘤机制及其对靶向药物疗效的影响

Antitumor mechanism of metformin and its effect on targeted drugs

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章15

编辑推荐

Metrics

本文评价